By ,
Published November 20, 2014
Swiss healthcare company Galenica said on Monday that its kidney drug PA21 successfully met primary and secondary endpoints in a late-stage trial, paving the way for regulatory filings in the United States, Europe and Switzerland.
Results of the six-month phase III study found that maintenance doses of PA21 were superior in sustaining the phosphate-lowering effect in patients with chronic kidney disease who are on dialysis versus a PA21 inactive low dose.
The company plans to submit PA21, which it developed in collaboration with Fresenius Medical Care, for regulatory approval in the fourth-quarter of 2012.
https://www.foxnews.com/health/galenicas-kidney-drug-meets-endpoint-in-trial